Home › Compound Library › 4-MMC (Mephedrone)

4-MMC (Mephedrone)

Stimulantoral · inferred

Synthetic cathinone (4-methylmethcathinone) and potent monoamine releaser affecting dopamine, serotonin, and norepinephrine. Short half-life of ~2h drives compulsive redosing. Effects last 2-3 hours per dose. Plasma concentrations peak at ~1.25h. More serotonergic than other cathinones, producing empathogenic effects similar to MDMA. Associated with cardiovascular toxicity, hyperthermia, and serotonin syndrome risk.

Projected serum levels — 200 mg, as needed (shown daily)

4-MMC (Mephedrone)
4-MMC (Mephedrone) modeled serum levels, 200 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 200 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 13.4 mg, trough ≈ 0.011 mg body load. Population-based estimate over 15 days for a 200 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Stimulant
Route modeled
Oral
Model confidence
inferred
Half-life
2.2 h
Common dose
200 mg
Reference dose range
100–400 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
200 mg oral — Cmax 0.14 mg/L at 1.3 h

Documented interactions

  • danger
    Berberine + 4-MMC (Mephedrone) CYP inhibition

    Berberine reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    Bupropion (Wellbutrin) + 4-MMC (Mephedrone) CYP inhibition

    Bupropion (Wellbutrin) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    CBD (Cannabidiol) + 4-MMC (Mephedrone) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    Celecoxib (Celebrex) + 4-MMC (Mephedrone) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    Citalopram (Celexa) + 4-MMC (Mephedrone) CYP inhibition

    Citalopram (Celexa) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    Contrave (Naltrexone/Bupropion) + 4-MMC (Mephedrone) CYP inhibition

    Contrave (Naltrexone/Bupropion) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

Serum checks 37 modeled interaction pairings for 4-mmc (mephedrone) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Human Pharmacology of Mephedrone in Comparison with MDMA Papaseit E et al. · Neuropsychopharmacology, 2016 DOI

    First controlled human pharmacology study of mephedrone 200mg vs MDMA 100mg showing mephedrone elimination half-life of 2.15h (vs 8h for MDMA), earlier peak at 1.25h, and similar empathogenic profile.

  2. Pharmacokinetics of Mephedrone Enantiomers in Whole Blood after a Controlled Intranasal Administration to Healthy Human Volunteers Olesti E et al. · Pharmaceuticals, 2021 DOI

    Enantiomer-resolved PK showing S-mephedrone peaked earlier (39 min) with shorter half-life (1.63h) than R-mephedrone (45 min, 1.92h) after intranasal 150mg dosing.

2 published studies referenced in the app, each with a plain-language summary.